Stem cell transplantation for advanced hematologic Interleukin-12 (IL-12) has been reported to enhance the malignancies is limited largely by disease recurrence. [1] [2] [3] [4] [5] [6] cytolytic activity of NK and activated T cells and to Intensification of chemotherapy and radiation has had little induce low levels of lymphokine-activated killer (LAK) impact on post-transplant relapses. 7 Immunotherapeutic activity in normal human lymphocytes. Therapy with approaches may not cross-react with chemoradiotherapy, IL-12 has induced tumor eradication in murine models.
tested in a 51 Cr release assay for lysis of Daudi. PBL Interleukin-12 (IL-12), a 70-kDa heterodimeric cytokine, from 17 normal 'control' individuals were similarly induces immunomodulatory effects, some of which are tested and lysis was observed in only 3/17 (mean 16.9% similar to those induced by IL-2, but via independent pathof the three). By contrast, PBL from 10/12 patients ways. 20 In normal human PBL, IL-12 enhances the cytoobtained a median of 30 days after autoSCT, exhibited toxic activity of NK and activated T cells and can induce significant IL-12-induced LAK activity (mean lysis, very low levels of lymphokine-activated killer (LAK) 35.3%, P Ͻ 0.005 vs controls). PBL from 18 of 20 activity, mediated by CD56 + NK cells. [20] [21] [22] [23] [24] [25] IL-12 also patients tested a median of 44 days after alloSCT also enhances IL-2-induced LAK activity. [22] [23] [24] [25] [26] A high affinity exhibited significant LAK activity (mean lysis, 30.0%, IL-12 receptor (IL-12r) has been identified on normal human P Ͻ 0.005 vs controls). In autoSCT recipients, IL-12 and NK and activated T cells and in some B cell lines. [27] [28] [29] A IL-2 at high concentrations (1000 U/ml each) were addisubunit of the IL-12r, the IL-12r␤1 chain, has been shown tive for induction of LAK activity, whereas low, suboptito be an essential component for the functional IL-12r since mal concentration of IL-12 (250 U/ml) and IL-2 (1 U/ml) the cytolytic activity is inhibited by antibodies to the ILwere synergistic in 3/5 experiments. The percentage 12r␤1 chain.
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of PBL expressing IL-12 receptor ␤1 chain In murine models, IL-12 has been shown to eradicate (IL-12r␤1) was higher in stem cell recipients than in some disseminated tumors. 30, 31 Moreover, in one murine normal individuals, P Ͻ 0.05. Moreover, a higher permodel, IL-12 has been reported to reduce GVHD without centage of IL-12r␤1-positive PBL was associated with abrogating the GVL effects.
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greater IL-12-induced LAK activity in transplant Interleukin-12 was recently found to induce LAK cytorecipients. These studies demonstrate that PBL toxicity in PBL from recipients of allogeneic T cellobtained early after stem cell transplantation have a depleted marrow. 33 However, the results may not necessarhigher percentage of cells expressing IL-12r␤1 and ily be applicable to recipients of autologous or of T cell respond to IL-12 with significantly greater LAK cytonon-depleted allogeneic marrow, because reconstitution of toxicity than PBL from normal controls. These results IL-12-responsive cells may be different and because recipisuggest that IL-12 is a potentially attractive candidate ents of T cell non-depleted cells are usually on immunosupfor study as consolidative immunotherapy after stem pressive drugs for prevention or treatment of GVHD, which cell transplantation.
might affect the ability of PBL to respond to cytokines. Keywords: interleukin-12; cytokines; stem cell trans-
In the present study, we determined that PBL obtained plant; immunotherapy from recipients of AutoSCT or T cell non-depleted alloSCT respond to IL-12 far more commonly and vigorously than do PBL from normal controls as measured by the generation of LAK activity, that combinations of IL-12 and IL-that the latter is associated with greater LAK activity. Figure 1a , PBL from only three of them exhibited ing malignancies; breast eight patients, AML two, ALL significant (у10%) lysis, with a mean (among the three) two, multiple myeloma two, non-Hodgkin's lymphoma of 17% at a 50:1 E:T ratio. Higher and lower concentrations two, ovarian one, and germ cell one. Blood was also of IL-12 (2500 and 10 U/ml) also failed to induce LAK obtained from 22 patients 21-119 (median 44) days after T activity in normal PBL (data not shown). By contrast cell non-depleted alloSCT for the following malignancies; (Figure 1b ), IL-12 induced LAK activity in PBL from 10 AML seven patients, CML six, myelodysplasia four, Hodgof 12 patients tested between 17 and 44 (median 29) days kin's disease one, non-Hodgkin's lymphoma two, multiple after autoSCT, with a mean lysis of 35.3% (P Ͻ 0.005 vs myeloma one, and CLL one. Four patients had received normal). Similarly, (Figure 1c ), IL-12 induced LAK PBSC and 18 marrow. At the time of sampling, all alloSCT activity in PBL from 18 of 20 patients tested between 25 patients were on cyclosporine, 11 were also on steroid therand 73 (median 40) days after alloSCT, with a mean lysis apy, and nine had active acute GVHD. Due to very low of 30.0%, (P Ͻ 0.005 vs normal PBL). A 5 day incubation lymphocyte counts in many stem cell recipients, not all and a concentration of 1000 U/ml IL-12 was found to be patients could be assessed by every study parameter. For optimal for LAK induction in post-transplant PBL (data comparison, blood was studied from 17 normal healthy not shown). individuals.
LAK assay IL-12 enhances IL-2-induced LAK activity in PBL from patients after AutoSCT and AlloSCT
Peripheral blood lymphocytes were obtained using FicollHypaque density gradient separation as previously Since LAK induction by IL-12 and IL-2 has been reported described. 34 LAK activity, defined as the lysis of NK-resistto be mediated via independent pathways, 20 the possibility ant tumor cells, was assessed by the ability of PBL, incuwas explored that the combination of cytokines might bated for 5 days at 37°C with IL-2 (Cetus Corporation, induce greater LAK activity than either cytokine alone. Emeryville, CA, USA) and/or IL-12 (kindly provided by Figure 2 depicts results of seven experiments conducted on Hoffman-LaRoche, Nutley, NJ, USA) as recombinant pur-PBL from autoSCT recipients in which high concentrations ified protein at a concentration of 0.36 mg/ml) to lyse of IL-12 (1000 U/ml) and/or IL-2 (1000 U/ml) were used. Daudi. LAK cultures were initiated and incubated in serumEach concentration had been identified as being optimal for free AIM V media (Gibco, Grand Island, NY, USA).
induction of LAK activity when used alone. The combiActivity was assessed by a 4-h 51 Cr release assay, as prenation was additive in four of seven experiments, and sigviously described. Percent lysis was determined according nificantly higher LAK activity was induced by the combito the formula: nation than by either cytokine alone (P Ͻ 0.01 vs IL-12 and P Ͻ 0.05 vs IL-2). To determine whether a combination % lysis = experimental c.p.m. − spontaneous c.p.m. maximal c.p.m. − spontaneous c.p.m. × 100 of the cytokines, each at a suboptimal concentration, would induce LAK activity in patient PBL, IL-12 and IL-2 were For this study, LAK activity was considered to be present used alone and in combination at 250 U/ml and 1 U/ml, if lysis was у10% at an effector:target ratio of 50:1.
respectively. Results from nine experiments on PBL from five autoSCT and four alloSCT recipients are shown in Figure 3 . The combination of IL-12 and IL-2 was synergistic Phenotypic analysis for LAK activity in three of five experiments with PBL from autoSCT recipients (P Ͻ 0.005 vs IL-12 alone and P Immunophenotyping of PBL was determined using rat antibody to the human IL-12r␤1 chain, (2B10), provided by Dr Ͻ 0.05 vs IL-2 alone). In PBL from alloSCT recipients, LAK activity induced by the combination of IL-12 and ILDavid Presky, (Hoffman-LaRoche) and used in an indirect staining technique with fluoresceinated goat anti-rat IgG 2 was significantly higher than that induced by either cytokine alone, in four of four experiments (P Ͻ 0.05). (Pierce, Rockford, IL, USA). Positively stained cells were
Stem cell recipients have a higher percentage of IL-12r␤1-positive PBL than normal controls
Phenotypic analysis was performed on PBL freshly obtained from nine autoSCT recipients, 11 AlloSCT recipients, and 11 healthy controls. As shown in Figure 4 , although the percentage of PBL which expressed the IL12r␤1 chain was quite variable, there was a significantly greater percentage of IL-12r␤1-positive PBL in transplant recipients than in healthy controls (P Ͻ 0.05).
A high percentage of cells expressing IL-12r␤1 is associated with high IL-12-induced LAK activity
Since the cytolytic activities of IL-12 have been determined to be mediated through the IL-12r␤1 chain, 27 studies were performed to determine whether the percentage of PBL after transplantation expressing IL-12r␤1 would correlate with PBL responsiveness to induction of LAK activity by IL-12. In 14 experiments on PBL from stem cell recipients, there was usually greater LAK activity observed in PBL which expressed a high percentage of IL-12r␤1. As depicted in Table 1 , PBL from six stem cell recipients that expressed IL-12r at a percentage of 30% or greater generated a mean of 54% IL-12-induced lysis of Daudi cells. In 14%) and two failed to generate LAK.
considerable evidence that a graft-versus-leukemia (GVL) effect, whether mediated by donor T cells, NK cells and/or Discussion by cytokine cascades, contributes to the benefit of alloSCT. [35] [36] [37] [38] Such effector mechanisms might be enhanced Disease recurrence remains the major limitation of stem cell transplantation for advanced malignancies. [1] [2] [3] [4] [5] [6] There is or induced by cytokines administered after alloSCT or even after autoSCT, at a time of minimal residual disease. NK been shown to upregulate the expression of IL-2r and IL12r, 22 to increase chemotaxis and adhesion ␤2 integrin cells capable of responding to IL-2 with LAK activity, are reconstituted early after transplantation. 17, 34, 39, 40 This and CD18 in NK cells, 48 and to increase cytotoxic granule formation, 26 all of which may contribute to the observed addiother observations have stimulated clinical trials in which IL-2, with or without exogenous LAK cells, have been tive or synergistic effects of the two cytokines. The effector cells which mediate IL-12-induced lytic administered early after stem cell transplantation in an effort to reduce relapse. 1, 11, 12, [15] [16] [17] 41 Phase I and II trials activity are predominantly CD56 + NK cells. 22 The greater responsiveness to IL-12 of PBL from stem cell recipients have demonstrated that IL-2 can be safely administered early after transplantation, 12, 16, 17, 41, 42 and ongoing phase III compared to normal PBL may be due to an increase in the percentage of CD56 after transplantation. The average trials will test the effect of such therapy on relapse and survival. 13, 14 percentage of PBL which expressed CD56 in 43 autoSCT and 30 alloSCT recipients tested in our laboratory was 21% Interleukin-12 shares several biological functions with IL-2, including stimulation of interferon-␥ secretion, and and 26% respectively, compared to 12% in 16 normal PBL (P Ͻ 0.01). the induction of cytolytic activity against tumor by NK and activated T cells. [20] [21] [22] [23] [24] 43 The latter function of IL-12 and IL-IL-12-induced activities, including NK/LAK activity, proliferation and IFN-␥ secretion, are mediated via binding 2 is thought to be mediated via independent pathways. 20 Hence, like IL-2, IL-12 is a potential candidate cytokine of IL-12 to the IL-12r which is expressed on activated NK and T cells. 27 In the present study, we observed that for studies of consolidative immunotherapy after transplantation.
although the percentage of PBL expressing IL-12r␤1 was highly variable, it was usually significantly higher in PBL IL-12 has been reported to induce low levels of LAK activity in PBL from a minority of healthy individfrom both autoSCT and alloSCT recipients than in PBL from normal individuals. Although PBL from some transuals. 23, 25, 26 Tests for additive or synergistic effects between IL-12 and IL-2 in the induction of LAK activity in normal plant recipients had a barely detectable percentage of cells expressing IL-12r␤1, but still exhibited detectable LAK human PBL have yielded conflicting results, including synergy, modest enhancement and even significant suppression activity, a high percentage of IL-12r␤1 expression was associated with greater IL-12-induced LAK activity. of LAK activity, depending on the concentration of cytokines and/or culture conditions used. [21] [22] [23] [24] 26 Although low percentages of IL-12r␤1 expression were observed in PBL from some autoSCT recipients who were In this study, IL-12-induced LAK activity in PBL from healthy individuals was uncommon and weak. By contrast, not on immunosuppressants, the PBL which expressed the lowest percentage of IL-12r␤1 were from alloSCT patients IL-12-induced LAK activity in PBL from autoSCT recipients was common and strong. In PBL from autoSCT recipion corticosteroid therapy for GVHD (data not shown). Steroids are known to decrease IL-2r expression 49 and may ents, the combination of IL-12 and IL-2, at concentrations which induced maximal LAK activity by each cytokine have a similar effect on IL-12r expression.
Recently it was reported that a variable percentage of when used alone, did not suppress and was additive while the combination of IL-12 and IL-2, each at suboptimal conresting PBL expressed IL-12r␤1 but did not bind measurable amounts of IL-12. 27 This suggests that expression of centrations, was often synergistic. These results show that PBL obtained from autoSCT recipients early after trans-IL-12r␤1 is a necessary, but not a sufficient condition for expression of functional IL-12r. This observation may plantation not only exhibit LAK activity after IL-12 stimulation but do so more frequently and at much higher levels explain why PBL from normal individuals failed to exhibit IL-12-induced LAK activity in this study, despite having a than PBL from normal individuals.
Studies of immunomodulatory effects of cytokines after moderate percentage of PBL expressing IL-12r␤1. Recently, cDNA encoding a second subunit of the human alloSCT are more complicated than after autoSCT because of the requirement for immunosuppressive therapy to pre-IL-12r has been isolated and designated IL-12r␤2. 50 Studies are underway to determine if IL-12-induced LAK activity vent or treat GVHD. Corticosteroids and cyclosporine are known to exert a myriad of suppressive effects on lymphois more closely associated with expression of the ␤2 chain. The use of cytokine therapy following AlloSCT is comcytes and IL-12-induced LAK activity is suppressed by hydrocortisone in vitro.
44-47 IL-12 has been found to stimuplicated by the concern that GVHD might be induced or exacerbated. That potential risk remains unknown. In a late LAK activity in PBL obtained from patients after T cell-depleted alloSCT, but these patients were not on phase I trial at our institution, IL-2 administered early after transplant of allogeneic T cell non-depleted marrow did not immunosuppressive drugs and not at high risk for GVHD. 33 We tested PBL from T cell non-depleted alloSCT recipiinduce acute GVHD in patients without GVHD off immunosuppressive therapy. 16 Although no relevant human ents, some of whom had GVHD at the time of study and all of whom were receiving cyclosporine and/or corticodata with IL-12 are available, IL-12 administered to mice after allogeneic BMT was found to inhibit GVHD without steroids. PBL from 18 of 20 alloSCT recipients responded to IL-12 with induction of LAK activity. Furthermore, a abrogating the GVL effect.
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In toto, the results presented provide a basis for considercombination of IL-12 and IL-2 used at suboptimal concentrations resulted in LAK activity that was greater than that ing IL-12 as an important potential candidate cytokine to be tested in clinical trials, alone or in combination with ILobserved with either cytokine used alone.
The mechanism by which the combination of IL-12 and 2, early after autoSCT or alloSCT, to determine if such post-transplant immunotherapy would reduce the relapse IL-2 induces greater cytolytic activity than either cytokine alone is not fully understood. In normal PBL IL-12 has rate.
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